The Pathophysiology, Diagnosis and Treatment of Allergic Rhinitis by Min, Yang-Gi
65 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org
INTRODUCTION
Allergic rhinitis (AR) is a symptomatic disorder of the nose in-
duced after exposure to allergens via IgE-mediated hypersensi-
tivity reactions, which are characterized by 4 cardinal symptoms 
of watery rhinorrhea, nasal obstruction, nasal itching and sneez-
ing.
1 The prevalence of AR is increasing all over the world. In the 
United States, AR is estimated to affect approximately 60 million 
peoples, and the prevalence is about 10-30% in adults and near-
ly 40% in children.
2-4 In Korea, the prevalence of perennial AR 
was 3.39% according to the survey of 71,120 patients who visited 
the otolaryngology clinics of 23 tertiary referral centers between 
November 1999 and April 2000.
5 According to the surveillance 
of 42,886 Koreans using the International Study of Asthma and 
Allergies in Childhood (ISSAC) questionnaire, 12-month prev-
alences of AR in elementary and middle school children (6-12 
and 12-15 years) were 28.8% and 29.1%, respectively.
6 AR is as-
sociated with an enormous economic burden causing problems 
in quality of life such as work/school performance and sleep. In 
the United States, direct cost for AR was 1.9 billion dollars in 
1996.
7 In another study, the direct cost for AR exceeded 3 billion 
dollars in 1996, and additional cost of 4 billion dollars resulted 
from comorbidities.
8 Furthermore, as many studies on the rela-
tionship between AR and asthma have been reported, there has 
been a growing interest in the treatment of AR. Therefore, Aller-
gic Rhinitis and Its Impact on Asthma (ARIA) published the 
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guidelines for AR and revised them in 2008.
9 The points of the 
ARIA guidelines are as follows: AR is subdivided by symptom 
duration and the severity of AR, a stepwise therapeutic approach 
is needed depending on the ARIA classification, and patients 
with persistent AR should be evaluated for asthma. There were 
some changes in the 2008 ARIA guidelines as compared to the 
2001 guidelines: (1) intranasal corticosteroid became a first-line 
drug which was second-line drug in the 2001 guidelines, (2) sec-
ond-generation antihistamines were preferred to first-generation 
one’s, (3) leukotriene antagonists were entered into suggested 
drugs and (4) the role of immunotherapy was re-evaluated.
We review herein the pathophysiology, ARIA classification, di-
agnosis and treatment of AR, including recent update of AR.
PATHOPHYSIOLOGY OF AR
Sensitization to allergens
Antigen presenting cells (APCs), such as dendritic cells in the 
mucosal surface, process allergens and present some peptides 
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from allergens on the major histocompatibility complex (MHC) 
class II molecule.
10 This MHC class II molecule and antigen 
complex take a role as the ligand of T-cell receptors on Naive 
CD4
+ T cells, which result in differentiation of Naive CD4
+ T 
cells to allergen-specific Th2 cell. Activated Th2 cells secret sev-
eral cytokines, which induce isotype switching of B cells to pro-
duce specific IgE and proliferation of eosinophils, mast cells 
and neutrophils (Fig. 1).
11 Produced antigen-specific IgE binds 
to high-affinity IgE receptors on mast cells or basophils.
Early and late reactions
When AR patients are exposed to allergens, allergic reactions 
develop in 2 different patterns according to time sequence. One 
is the early reaction, in which sneezing and rhinorrhea devel-
ops in 30 minutes and disappears. The other is the late reaction, 
which shows nasal obstruction approximately 6 hours after ex-
posure to allergens and subsides slowly. The early reaction is 
the response of mast cells to offending allergens (type I hyper-
sensitivity). Stimulated mast cells induce nasal symptoms by 
secreting chemical mediators such as histamine, prostaglan-
dins and leukotrienes.
12 In contrast to the early reaction, eo-
sinophil chemotaxis is the main mechanism in the late reac-
tion, which is caused by chemical mediators produced in the 
early reaction. Several inflammatory cells, eosinophils, mast 
cells and T cells migrate to nasal mucosa, break up and remod-
el normal nasal tissue,
13 and these processes result in nasal ob-
struction which is the main symptom of AR patients.
Neurogenic inflammation
When respiratory epithelium is destroyed and nerve endings 
are exposed by cytotoxic proteins from eosinophils, sensory 
nerve fibers are excited by nonspecific stimuli and stimulate 
both sensory afferent and surrounding efferent fibers, the so-
called retrograde axonal reflex. This makes the sensory nerve fi-
bers secrete neuropeptides such as substance P and neuroki-
nin A, which induce contraction of smooth muscles, mucous 
secretion of goblet cells and plasma exudation from capillaries. 
This process is called neurogenic inflammation.
14
Non-specific hyperresponsiveness
Non-specific hyperresponsiveness is one of the clinical char-
acteristics of allergic inflammation. Due to eosinophilic infiltra-
tion and destruction of nasal mucosa, the mucosa becomes hy-
peractive to normal stimuli and causes nasal symptoms such as 
sneezing, rhinorrhea, nasal itching and obstruction.
15 This is a 
non-immune reaction that is not related to IgE. Hypersensitivi-
ty to non-specific stimuli such as tobacco or cold and dry air as 
well as specific allergens increases in AR patients.
Relationship between AR and asthma - “One airway, one disease”
Epidemiologic studies have reported that almost all of the asth-
ma patients have AR symptoms
16,17 eosinophilic inflammation 
of nasal mucosa regardless of nasal symptoms.
18 This character-
istic finding of asthma is not found in patients with other pul-
monary diseases and is the evidence that asthma is a systemic 
disease. The prevalence of asthma in AR patients has been re-
ported to be from 10% up to 40%.
5,16,19-21 Several clinical studies 
have revealed that although AR patients do not have asthma, 
they can have eosinophilic infiltration in bronchial mucosa.
22-25 
Madonini et al.
26 have indicated that AR patients with positivity 
to pollens have bronchial hyperresponsiveness during the pol-
len season. Corren et al.
27 have demonstrated that allergen stim-
Fig. 1.  Allergen-induced sensitization and inflammation.
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ulation to nasal mucosa in AR patients induces bronchial hyper-
responsiveness. With cumulative of evidence for structural an-
alog
28,29 and the similarity of allergic inflammatory cells, inflam-
matory mediators and cytokines between upper and lower air-
ways,
13,30 the “one airway, one disease” concept has been intro-
duced. This means that since AR and asthma are not separate 
disease entity, concurrent asthma in AR patients and concur-
rent AR in asthmatic patients should be indentified and both 
upper and lower airway allergy should be treated simultane-
ously. The ARIA (2008) recommends that asthma should be 
evaluated in moderate-severe persistent AR patients.
THE ARIA CLASSIFICATION OF AR
In the past, AR was subdivided by the kind of allergens into 
seasonal or perennial AR. The later is caused by indoor aller-
gens such as house dust mites, cockroaches, animal dander or 
fungi, and the former by outdoor allergens, pollens. However, 
in some areas, pollens can induce perennial AR when patients 
are exposed to the pollens adhering to indoor carpet, furniture 
or bedclothes after the pollen season. In addition, perennial AR 
symptoms do not persist all around the year, and seasonal AR 
patients sensitized to multiple allergens may have rhinitis symp-
toms in all seasons. Furthermore, there are seasonal exacerba-
tions in perennial AR patients when they are exposed to pollens. 
For these reasons, in 2001, ARIA suggested “intermittent” and 
“persistent” instead of “seasonal” and “perennial” .
1 Also, disease 
severity was classified as “mild” and “moderate-severe” consid-
ering its influence on work/school performance, daily activities 
and sleep (Fig. 2).
DIAGNOSIS OF AR
The diagnosis of AR is based on a typical history of allergic 
symptoms and diagnostic tests.
9 When 2 or more symptoms 
out of watery rhinorrhea, sneezing, nasal obstruction and nasal 
pruritus persist for ≥1 hour on most days, AR is strongly sus-
pected. In this situation, disease severity should be classified 
according to the ARIA guidelines and a confirmative diagnosis 
should be established by the skin prick test or the serum-specif-
ic IgE level. Unilateral nasal stuffiness, mucopurulent rhinor-
rhea, mucoid postnasal drip, pain, recurrent epistaxis or anos-
mia is usually not associated with AR.
Skin testing
Skin testing is the most important to find offending allergens. 
There are various testing methods including the scratch, prick/
puncture, intradermal and patch tests. Among them, the skin 
prick test is usually recommended in clinical practice. False-
positive or false-negative reactions are frequently evoked in 
skin tests, which means that positive reactions to specific aller-
gens in skin tests does not always have a direct correlation with 
actual allergic reactions in the nasal cavity. There is controversy 
regarding the interpretation of the test results, and criteria for 
positivity are different among allergy clinics. Furthermore, skin 
tests have some problems. This test can be influenced by some 
drugs, particularly antihistamines, patients’ age and test sites. If 
a patient has dermatologic disease, skin tests are difficult to 
perform. Despite these weak points, skin testing is regarded as 
the most important diagnostic method. A previous study on 
skin prick test results of 1,564 Korean AR patients reported that 
house dust mites was the most common allergen with a posi-
tive reactivity of 70%-80% (Table 1).
31
Serum specific IgE level
Although the radioallergosorbent test (RAST) was the first 
method to detect serum-specific IgE, this test has not been 
widely used because it requires a radioactive isotope and ex-
pensive equipment and also because this test cannot detect 
multiple antibodies simultaneously. The next method is the 
multiple allergen simultaneous test (MAST). Since the MAST 
has some advantages over the RAST, it has been widely used. 
The MAST uses a photo reagent instead of a radioactive iso-
tope, does not require expensive equipment and can detect 
Fig. 2.  ARIA classification of severity of allergic rhinitis.
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multiple allergens simultaneously. This test is not affected by 
drugs such as antihistamines, is less invasive and can be adopt-
ed in patients with dermographism. One problem with the 
MAST is a low sensitivity as compared to the skin prick test. 
However, Finnerty et al.
32 reported that the MAST shows 66.5% 
and 78.5% concordance rates when the criteria for positivity are 
≥3 mm and ≥5 mm, respectively, and they recommended the 
MAST rather than skin tests. The capsulated hydrophilic carrier 
polymer (CAP) system is a more accurate in vitro test. Its proce-
dure is similar to that of the MAST, but it uses a solid phase that 
has a high affinity to antigens. The CAP system can detect aller-
gens more quantitatively than the MAST using antigens bound 
to a fine thread because antigens bind to the inner surface of 
sponge-like cellulose polymer bubbles.
Clinical parameters related to asthma
Guerra et al.
33 have reported that the severity of AR has a posi-
tive link with asthma and the risk of asthma incidence is 5 times 
higher in AR patients with elevated serum IgE. Silvestri et al.
34 
have pointed out that the eosinophil count of the nasal cavity is 
related to bronchial hyperresponsiveness and that the changes 
in the number and distribution of eosinophils after nasal mu-
cosal challenge are also associated with bronchial hyperrespon-
siveness. They suggest that the local inflammation of AR can 
predict bronchial hyperresponsiveness. A domestic study of 83 
pediatric AR patients and 32 normal children reported that prev-
alence of bronchial hyperresponsivenss was higher in AR pa-
tients than in control subjects (32.5% vs. 9.4%) and that persis-
tent AR and parental asthma are closely related to bronchial  
hyperresponsiveness.
35 In addition, it is known that bronchial 
hyperresponsiveness in AR patients is a predictor of asthma.
36 It 
has generally recognized that the development and severity of 
asthma increase when a patient is sensitized to indoor allergens 
such as house dust mites or cat dander. The prevalence of asth-
ma further increases in moderate to severe AR patients sensi-
tized to both indoor and outdoor allergens.
TREATMENT
Avoidance
Avoidance of indoor allergens including house dust mites is 
sometimes difficult. Therefore, few studies on avoidance of of-
fending allergens have been conducted. For this reason, the 
2001 ARIA guidelines classified the avoidance as evidence D.
1 
The 2008 ARIA guidelines have reported that there is the lack of 
evidence for effectiveness of avoidance of house dust mites or 
pet animal dander.
9 However, a previous study has shown that 
cleaning with 60°C hot water removes house dust mites and 
other allergens effectively as compared to 30°C water (26.8% vs. 
0.6%).
37 Avoidance is mandatory for occupational AR. The Eu-
ropean Academy of Allergy and Clinical Immunology (EAACI) 
stated that the safest and most effective treatment of occupa-
tional AR is the strict avoidance of offending allergens.
38
Pharmacological treatment
The principle of pharmacological treatment is a stepwise ap-
proach according to the severity and duration (Fig. 3). The 2008 
ARIA guidelines are different from the 2001 ARIA guidelines as 
follows: (1) leukotriene receptor antagonists can be used in all 
AR, (2) second-generation antihistamines are preferred to first-
generation antihistamines and (2) topical steroids are regarded 
as the most effective drug for adult and pediatric AR patients.
Oral antihistamines
First-generation antihistamines, which have been used since 
the early 1940s, have some side effects such as sedation, mem-
ory impairment and psychomotor dysfunction, which cause 
many problems in clinical practice. In contrast, second-genera-
tion antihistamines penetrate the blood-brain barrier much 
less than first-generation antihistamines, and thus they have 
few side effects on the central nervous system.
39 Therefore, the 
2008 ARIA guidelines recommended second-generation anti-
histamines rather than first-generation antihistamines. Oral an-
tihistamines are effective in the treatment of rhinorrhea, sneez-
ing, nasal itching and eye symptoms but less effective in nasal 
obstruction.
40 Oral antihistamines have been reported to be safe 
and effective in children.
41 Terfenadine and astemizole were 
initially used second-generation antihistamines. These drugs 
have severe cardiac toxicity inducing QT prolongation and tor-
sade de pointes. When these antihistamines are administered 
along with macrolide antibiotics or azole antifungal agents, the 
risk of cardiac side effects is elevated because these drugs affect 
cytochrome p450 isoenzyme CYP3A4 activity. Therefore, ter-
fenadine and astemizole have not been prescribed in many 
countries. Since ebastine is metabolized by CYP3A4, it can also 
Table 1.  Positive rates of common offending aeroallergens (n=1,564)
Allergens Positive rate (%)
Mite
Dermatophagoides farinae
Dermatophagoides pteronyssinus
77.6
73.3
Epithelia
Cat hair
Dog hair
39.9
32.6
Pollens
Mugwort
Tree
Ragweed
Grass
23.4
18.8
18.2
14.1
Others
Cockroach
Fungus
21.8
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induce such drug interactions theoretically. When high-dose 
ebastine (50 mg/kg/day) is given to guinea pigs, QT prolonga-
tion is observed in electrocardiography. When ebastine 20 mg/
kg/day is administered with ketoconazole 400 mg/kg/day or 
erythromycin 2,400 mg/kg/day, QT intervals are prolonged up 
to 10 m sec with no clinical significance. Care should be taken 
in prescribing ebastine along with other drugs inhibiting CY-
P3A4 in patients with previous QT prolongation, liver failure or 
renal dysfunction.
Intranasal antihistamines
Topical antihistamines have been reported to reduce itching, 
sneezing and rhiorrhea.
42 However, they are less effective than 
intranasal corticosteroids and ineffective in eye symptoms.
43 In-
tranasal azelastine twice a day can reduce the symptoms of sea-
sonal AR patients who do not respond to oral antihistamines. 
They have some side effects such as mild sedation and metallic 
taste.
44
Intranasal corticosteroids
Since intranasal corticosteroids are not absorbed systemical-
ly, they induce few systemic side effects. Steroid particles pene-
trate the cellular membrane and bind to cytoplasmic steroid re-
ceptors. The steroid-receptor complex is transferred to the nu-
cleus and binds to the specific DNA site. The anti-inflammatory 
effect is induced by alteration in protein synthesis after binding 
of the steroid-receptor complex to DNA or by affecting other 
transcription factors. Intranasal corticosteroids inhibit both 
early and late reactions and reduce IgE production and eosino-
philia by inhibiting the secretion of cytokines including IL-4, 
Fig. 3.  Rhinitis management.
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1L-5 and IL-13. When intranasal corticosteroids are adminis-
tered, eosinophils and basophils decrease in 1 week.
45 Intrana-
sal corticosteroids are effective in all AR symptoms, especially 
nasal obstruction and eye symptoms.
46 The therapeutic effect of 
intranasal corticosteroids is encountered 7 hours after adminis-
tration
47 and reaches the maximal level after 2 weeks.
Recently, budesonide, triamcinolone acetonide, fluticasone 
propionate, mometasone furoate and fluticasone furoate have 
been widely used. For a better choice of topical steroids, their 
pharmacological characteristics should be considered. Although 
these drugs have similar clinical effects, their systemic absorp-
tion rates are different. The systemic absorption rates of fluni-
solide, triamcinolone acetonide and beclomethasone dipropi-
onate are 20-50%, whereas those of mometasone furoate and 
fluticasone propionate are very low (≤0.1% and ≤2%, respec-
tively). In addition, most of the intranasal corticosteroids are 
eliminated by first-pass hepatic metabolism.
Currently prescribed intranasal corticosteroids are thought to 
be safe. Even when children aged 7-12 years use mometasone 
200 μg or budesonide 400 μg for 2 weeks, their growth rates of 
the lower extremities are not significantly affected. Twelve-
month use of beclomethasone dipropionate may cause growth 
retardation in children.
48 However, 1-year mometasone or fluti-
casone therapy in children do not cause growth retardation.
49,50
Intranasal corticosteroids usually improve the symptoms of 
patients with asthma. Watson et al.
51 have documented that in-
tranasal beclomethasone therapy reduces bronchial hyperre-
sponsiveness and asthmatic symptoms in patient with AR and 
asthma. Foresi et al.
52 have demonstrated that fluticasone pro-
pionate suppresses bronchial hyperresponsiveness in patients 
with seasonal AR.
Leukotriene receptor antagonists (LTRAs)
The role of leukotrienes in allergic reactions is well known. The 
efficacy of LTRA has been demonstrated in asthma. Recently, 
some studies on the efficacy of LTRAs in AR patients have been 
reported. As previously mentioned, the 2008 ARIA guidelines 
re-evaluated the role of LTRAs. Interest in LTRAs has been in-
creasing with the concept of “one airway, one disease” , and there-
fore many studies on LTRAs are being conducted. Pranlukast 
(Onon
®), montelukast (Singulair
®) are commercially available. 
Care should be taken in the clinical use of Pranlukast which is 
metabolized by hepatic CYP3A4 enzymes because its serum 
concentration can be elevated when administered with terfen-
adine, astemizole, ketoconazole or erythromycin.
Montelukast is effective in reducing nasal and eye symptoms 
in patients with seasonal AR and improves nasal obstruction 
comparable to loratadine.
9 The additive or synergic effect of 
montelukast and loratadine is controversial. Some previous 
studies have advocated that a combination of montelukast and 
loratadine has faster and a better efficacy than montelukast or 
loratadine alone,
53 whereas others have not.
54 Kurowski et al.
55 
reported that montelukast plus cetirizine which was adminis-
tered 6 weeks before the pollen season effectively prevented the 
exacerbation of seasonal AR symptoms. The additive effect of 
LTRAs and antihistamines requires more investigations. Up to 
now, the pharmacological effects of LTRAs are estimated to be 
similar to those of antihistamines but less than those of intrana-
sal corticosteroids in patients with seasonal AR.
9
Anti-IgE antibody
Omalizumab, an anti-IgE recombinant humanized monoclo-
nal antibody, interferes with the interactions between mast 
cells/eosinophils and IgE by binding to free IgE and hence low-
ers serum free IgE.
56 It also suppresses inflammatory reactions 
in blood or nasal mucosa
57 and expression of FceRI located on 
the surface of mast cells or eosinophils.
58 Casale et al.
59 have 
demonstrated that omalizumab pretreatment (300 mg) just be-
fore and during the pollen season for 12 weeks with 3-4 weeks 
intervals reduces AR symptoms significantly in patients with 
severe seasonal AR. Although there were some adverse reac-
tions, they stated that the incidence of adverse effects of omali-
zumab such as headache, upper respiratory infection and si-
nusitis in the patient group is not significantly different from 
that of the placebo group. Urticaria may occur at the injection 
site, but it subsides spontaneously or with the administration of 
antihistamines. While anti-IgE antibody therapy appears to be 
helpful in severe asthma, it is controversial whether anti-IgE 
therapy is suitable as a treatment option for AR due to anaphy-
lactic risk
60 and high costs.
Immunotherapy
Immunotherapy is the only therapeutic option that modifies 
the basic allergic mechanism by inducing desensitization and 
producing an anergy state for offending allergens. Immuno-
therapy was initially introduced for seasonal AR due to pollens. 
At present, its indications have been extended to other allergic 
diseases due to hymenoptera, house dust mite, animal dander 
or fungi.
61 Extracts of offending allergens are injected subcuta-
neously with increasing doses until a maintenance dose is 
reached. The maintenance dose is administered for ≥3 years. 
Although subcutaneous immunotherapy is a well-established 
treatment option, the risk of anaphylaxis has led to the develop-
ment of other administration routes such as the oral, sublingual 
or nasal route. Sublingual immunotherapy (SLIT) has been used 
for 20 years in European countries because of its non-invasive-
ness, low incidence of adverse effects and convenience of self-
administration. Recently, it has replaced subcutaneous immu-
notherapy. In Korea, sublingual immunotherapy for house dust 
mites was initiated in 2007.
62
Taken together, immunotherapy is effective in house dust mite 
and pollen AR of adult and children, prevents asthma in AR pa-
tients and reduces new atopic sensitization. Its long-term effect 
after discontinuation of immunotherapy has been demonstrat-Allergy Asthma Immunol Res. 2010 April;2(2):65-76.  doi: 10.4168/aair.2010.2.2.65
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ed. Herein we describe SLIT whose safety and efficacy have been 
proven.
Mechanism of SLIT
Recently, many studies on immunologic changes after SLIT 
have been conducted. Regulation of antigen-specific responses 
(an increase in the IgG4/IgE ratio), inhibition of recruitment/
activation of inflammatory cells, shift of Th2 to Th1 responses 
and activation of regulatory T cells are the main mechanisms of 
SLIT.
63 Regulatory T cells are known to play a crucial role in im-
mune tolerance, and they are related to the mechanism of SLIT. 
High-dose allergen extracts for SLIT induce regulatory T cells, 
which inhibit allergic inflammatory reactions by suppressing 
Th2 cells and producing IL-10 and TGF-b (Fig. 4).
64
Clinical efficacy
During the last 20 years, researches into SLIT have mainly been 
conducted in European countries. Although most studies have 
included a small sample size, meta-analyses of these studies 
have recently been published. A meta-analysis of 22 trials and 
979 subjects showed that SLIT reduced the symptom score and 
medication frequency.
65 In this meta-analysis, the symptom 
score and medication frequency were not improved in children. 
However, this study has some limitations due to the small sam-
ple size.
66 Another meta-analysis of pediatric patients aged 4-18 
years have suggested that SLIT reduces allergic symptoms and 
medication score.
67 A previous study conducted in Korea re-
ported that subjective symptoms assessed with a questionnaire 
were improved 6 months after SLIT, and 45% of patients were 
satisfied with SLIT.
62
Like subcutaneous immunotherapy, SLIT reduces the inci-
dence of asthma.
68 A long-term follow-up study of pediatric pa-
tients with asthma and AR who were treated with SLIT for 4-5 
years have pointed out that SLIT decreases the symptoms of 
asthma, medication frequency, and peak expiratory flow rate, 
and its efficacy is maintained for 4 to 5 years after discontinua-
tion.
69
SLIT has been shown to reduce sensitization to new allergens. 
In a previous study in 216 patients, it was found that 5.9% of pa-
tients in the SLIT group showed positive skin test results to new 
allergens, whereas 38% of patients in the control group, suggest-
ing that SLIT could prevent sensitization to new allergens.
70
Safety of SLIT
SLIT is safer than subcutaneous immunotherapy. Common 
adverse events are local reactions (oral pruritus or swelling) 
and gastrointestinal problems (nausea, vomiting, diarrhea or 
abdominal pain), which subside spontaneously or with conser-
vative management. Fatal adverse events causing death or se-
vere sequelae have not yet been reported. Three cases of ana-
phylaxis after SLIT have been reported in the English language 
literatures: 2 of them were due to a mixture of multiple aller-
gens and the remaining occurred during the treatment with la-
tex allergen.
71-73 However, anaphylaxis caused by commercially 
available allergens has not yet been reported. When 66 reports 
on SLIT were analyzed, there were no serious adverse effects 
during 1,181,654 administrations for 4,378 patients.
74 Of the 66 
reports, 41 reported adverse events: 1,047 adverse events oc-
curred during 386,149 doses (2.7/1,000 doses). In 49 reports, 
529 (12%) of 4,378 patients showed adverse events. Of 314,959 
doses, 169 (0.056%) induced systemic side reactions and exac-
erbation of asthma occurred in 7 patients. In a previous study 
with 126 patients aged 3-5 years who underwent SLIT for aller-
gic respiratory disease for ≥2 years, 9 adverse events were iden-
tified, which occurred during the dose escalation: 2 cases of 
oral pruritus, 1 case of mild abdominal pain and 6 cases of gas-
trointestinal problems, and all cases were successfully treated 
by decreasing doses.
69 Therefore, SLIT is thought to be safe, even 
for children aged ≤5 years. Table 2 shows the level of evidence 
of different interventions in allergic rhinitis.
Fig. 4.  The possible mechanism of action of sublingual immunotherapy.
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OTHER COMPLICATIONS AND COMORBID DISEASES
Allergic conjunctivitis
Allergic conjunctivitis is one of the most common accompa-
nying diseases of AR. This is attributable to outdoor allergens 
such as pollens rather than indoor allergens. About 75% of AR 
patients complain of the symptoms of allergic conjunctivitis.
Rhinosinusitis
Influence of AR on the paranasal sinuses is not well under-
stood. Many studies have suggested that allergic inflammation 
could affect acute or chronic rhinosinusitis. In AR patients due 
to ragweed, abnormal findings in computed tomography are 
found during the ragweed pollen season.
75 A previous radiolog-
ic study using computed tomography has demonstrated that 
Table 2.  Level of evidence of different interventions in allergic rhinitis
9
Seasonal rhinitis Perennial rhinitis (mostly applies  
for studies ≤4 weeks)*
Persistent  
rhinitis
†
Intervention Adults Children Adults Children
H1-antihistamine
Oral
Intranasal
Intraocular
A
A
A
A
A
A
A
A
B
A
A
B
A
No data
No data
Glucocorticosteroid
Intranasal
Oral
IM
A
A
A
A
B
B
A
B
B
A
B
B
No data
No data
No data
Cromones
Intranasal
Intraocular
A
A
A
A
A
B
B
B
No data
No data
NAAGA (topical) B C C C No data
Antileukotriene A A over 6 years No data
Decongestant
Intranasal
Oral
Oral + H1-antihistamine
C
A
A
C
B
C
B
C
B
No data
No data
No data
Anticholinergic A A No data
Homeopathy D D D D No data
Acupuncture D D D D No data
Phytotherapy B D D D No data
Other CAM D D D D No data
Specific immunotherapy: rhinoconjunctivitis
Subcutaneous
Sublingual
‡
A
A
A
A
A
A
A
A
No data
No data
Intranasal
‡ A No data
Specific immunotherapy: asthma
Subcutaneous
Sublingual
‡
A
A
A
A
A
A
A
A
Anti-IgE A A over 12 years A A over 12 years No data
Allergen avoidance
House dust mites
Other indoor allergens
Total avoidance of occupational agent
Partial avoidance of latex
D
D
D
D
D
D
A (for asthma)
B
D
D
No data
No data
No data
No data
*Very few studies longer than 4 weeks.
†Applies to treatments only carried out in studies with persistent rhinitis.
‡Applied to high-dose treatment.Allergy Asthma Immunol Res. 2010 April;2(2):65-76.  doi: 10.4168/aair.2010.2.2.65
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nasal allergen challenge can induce paranasal sinus inflamma-
tion.
76 However, epidemiologic studies have suggested that the 
incidence of rhinosinusitis is not significantly higher in AR pa-
tients than in normal subjects. Therefore, it is not clear whether 
AR play a critical role in the development of rhinosinusitis. An-
tihistamines improve nasal symptoms such as sneezing or na-
sal obstruction in AR patients with acute rhinosinusitis.
77
It is noteworthy that long-term use of nasal decongestants in 
AR patients may cause ciliary dysfunction with subsequent ir-
reversible chronic hypertrophic rhinitis or sinusitis. In an ani-
mal study using rabbits, long-term administration of deconges-
tants induced histologic and functional changes of cilia and re-
sulted in ciliary dysfunction and rhinosinusitis.
78
Nasal polyposis
The relationship between nasal polyposis and allergy is not 
clear. It has been suggested that atopy itself may not contribute 
to the pathophysiology of nasal polyposis because the expres-
sion of IL-4, IL-5 and IFN-g is not significantly different between 
nasal polyps of patients with seasonal AR and those with infec-
tious rhinitis.
79 Mechanisms involving edema and protrusion of 
nasal mucosa in nasal polyposis are similar to the pathophysi-
ology of AR.
80
Adenoid hypertrophy
Sensitization to inhalant allergens can alter immunological 
parameters of the adenoid. The numbers of CD1a+ Langerhans 
cells, eosinophils and IL-4 or IL-5-producing inflammatory cells 
increase in adenoid tissue of AR patients.
81,82 The degree of ade-
noid hypertrophy does not seem to correlate with the presence 
of atopy.
83 Although there have been few reports on the efficacy 
of antihistamines in AR patients with adenoid hypertrophy, in-
tranasal corticosteroids are known to improve the symptoms of 
adenoid hypertrophy regardless of the presence of atopy. A re-
cent study reported that the consecutive administration of short-
term oral steroid and long-term antihistamines/intranasal cor-
ticosteroids reduce the size of adenoid and improve the symp-
toms of adenoid hypertrophy.
84
Eustachian tube dysfunction and otitis media with effusion
Since the nasal mucosa is lined with the respiratory epitheli-
um, allergic reactions due to inhalant allergens can occur in the 
eustachian tube. Therefore, the eustachian tube function of AR 
patients is impaired and otitis media with effusion occurs fre-
quently, especially in children. It is controversial whether aller-
gic inflammation in the eustachian tube is a reaction to local ir-
ritation or part of systemic reaction.
Middle ear effusion fluid taken from AR patients contains IL-4 
and IL-5 secreting cells.
82 This represents a positive relationship 
between AR and the development of otitis media with effusion. 
It might be helpful to check the presence of allergy in patients 
with recurrent middle ear effusion.
85
Changes in cognitive abilities
Although cognitive abilities in AR patient have not yet been 
studied, there is growing interest in this issue. Learning or cog-
nitive problems should be considered as psychological compli-
cations of AR. AR patients do not concentrate on their school 
work due to sneezing, rhinorrhea or nasal itching. Marshall et 
al.
86 reported that during ragweed season, allergic reactions to 
ragweed pollens cause a decrease in the speed of cognitive pro-
cessing and difficulties in working memory in patients with 
ragweed AR. Symptomatic AR is related to poor school perfor-
mance.
87
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